These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. Saiki S; Hatano T; Fujimaki M; Ishikawa KI; Mori A; Oji Y; Okuzumi A; Fukuhara T; Koinuma T; Imamichi Y; Nagumo M; Furuya N; Nojiri S; Amo T; Yamashiro K; Hattori N Sci Rep; 2017 Aug; 7(1):7328. PubMed ID: 28779141 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385 [TBL] [Abstract][Full Text] [Related]
4. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Christopher L; Marras C; Duff-Canning S; Koshimori Y; Chen R; Boileau I; Segura B; Monchi O; Lang AE; Rusjan P; Houle S; Strafella AP Brain; 2014 Feb; 137(Pt 2):565-75. PubMed ID: 24334314 [TBL] [Abstract][Full Text] [Related]
5. Lipid metabolic dysregulation is involved in Parkinson's disease dementia. Dong MX; Wei YD; Hu L Metab Brain Dis; 2021 Mar; 36(3):463-470. PubMed ID: 33433787 [TBL] [Abstract][Full Text] [Related]
6. Accuracy of Patient and Care Partner Identification of Cognitive Impairments in Parkinson's Disease-Mild Cognitive Impairment. Copeland JN; Lieberman A; Oravivattanakul S; Tröster AI Mov Disord; 2016 May; 31(5):693-8. PubMed ID: 27028432 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. Delgado-Alvarado M; Gago B; Navalpotro-Gomez I; Jiménez-Urbieta H; Rodriguez-Oroz MC Mov Disord; 2016 Jun; 31(6):861-81. PubMed ID: 27193487 [TBL] [Abstract][Full Text] [Related]
8. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease. Uysal-Cantürk P; Hanağası HA; Bilgiç B; Gürvit H; Emre M Eur J Neurol; 2018 Jan; 25(1):148-153. PubMed ID: 28941002 [TBL] [Abstract][Full Text] [Related]
9. Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles. Graham SF; Rey NL; Yilmaz A; Kumar P; Madaj Z; Maddens M; Bahado-Singh RO; Becker K; Schulz E; Meyerdirk LK; Steiner JA; Ma J; Brundin P J Proteome Res; 2018 Jul; 17(7):2460-2469. PubMed ID: 29762036 [TBL] [Abstract][Full Text] [Related]
10. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Ekman U; Eriksson J; Forsgren L; Mo SJ; Riklund K; Nyberg L Lancet Neurol; 2012 Aug; 11(8):679-87. PubMed ID: 22742929 [TBL] [Abstract][Full Text] [Related]
11. Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson's disease related anxiety disorder. Dong MX; Hu L; Wei YD; Chen GH Neurosci Lett; 2021 Feb; 745():135626. PubMed ID: 33440238 [TBL] [Abstract][Full Text] [Related]
12. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis. Han W; Sapkota S; Camicioli R; Dixon RA; Li L Mov Disord; 2017 Dec; 32(12):1720-1728. PubMed ID: 28880465 [TBL] [Abstract][Full Text] [Related]
13. Deep-learning detection of mild cognitive impairment from sleep electroencephalography for patients with Parkinson's disease. Parajuli M; Amara AW; Shaban M PLoS One; 2023; 18(8):e0286506. PubMed ID: 37535549 [TBL] [Abstract][Full Text] [Related]
14. A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study. Troisi J; Landolfi A; Vitale C; Longo K; Cozzolino A; Squillante M; Savanelli MC; Barone P; Amboni M Metabolomics; 2019 Jun; 15(6):90. PubMed ID: 31183578 [TBL] [Abstract][Full Text] [Related]
15. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting. Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939 [TBL] [Abstract][Full Text] [Related]
16. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS. Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189 [TBL] [Abstract][Full Text] [Related]
18. Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk. Tunold JA; Tan MMX; Toft M; Ross O; van de Berg WDJ; Pihlstrøm L Mov Disord; 2024 Mar; 39(3):596-601. PubMed ID: 38124396 [TBL] [Abstract][Full Text] [Related]